Samsara BioCapital LLC Sells 399,637 Shares of HilleVax, Inc. (NASDAQ:HLVX)

Samsara BioCapital LLC lessened its position in shares of HilleVax, Inc. (NASDAQ:HLVX - Free Report) by 50.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 399,637 shares of the company's stock after selling 399,637 shares during the quarter. Samsara BioCapital LLC owned about 0.80% of HilleVax worth $827,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the company. Intech Investment Management LLC purchased a new position in HilleVax in the fourth quarter worth about $26,000. SG Americas Securities LLC lifted its stake in shares of HilleVax by 61.6% in the 4th quarter. SG Americas Securities LLC now owns 18,145 shares of the company's stock valued at $38,000 after purchasing an additional 6,916 shares during the last quarter. Ieq Capital LLC boosted its holdings in shares of HilleVax by 71.1% in the 4th quarter. Ieq Capital LLC now owns 22,495 shares of the company's stock worth $47,000 after purchasing an additional 9,344 shares during the period. Bank of Montreal Can increased its position in shares of HilleVax by 47.1% during the 4th quarter. Bank of Montreal Can now owns 35,763 shares of the company's stock valued at $74,000 after purchasing an additional 11,459 shares during the last quarter. Finally, Russell Investments Group Ltd. raised its holdings in HilleVax by 328.0% during the 4th quarter. Russell Investments Group Ltd. now owns 38,236 shares of the company's stock valued at $79,000 after buying an additional 29,303 shares during the period. Institutional investors own 86.42% of the company's stock.

HilleVax Stock Performance

HilleVax stock traded up $0.03 during mid-day trading on Friday, hitting $1.96. The company's stock had a trading volume of 417,706 shares, compared to its average volume of 446,545. HilleVax, Inc. has a one year low of $1.34 and a one year high of $16.31. The stock has a market cap of $98.28 million, a PE ratio of -0.63 and a beta of 0.86. The company has a 50 day moving average of $1.70 and a 200-day moving average of $1.84.

HilleVax (NASDAQ:HLVX - Get Free Report) last posted its quarterly earnings results on Friday, March 28th. The company reported ($0.35) EPS for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.02). On average, equities research analysts forecast that HilleVax, Inc. will post -2.64 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a "neutral" rating and set a $2.00 price objective on shares of HilleVax in a research report on Monday, March 31st. Six research analysts have rated the stock with a hold rating, According to MarketBeat.com, the company has a consensus rating of "Hold" and a consensus target price of $3.00.

HilleVax Profile

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.